GILDGilead SciencesFinished
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Locally Advanced or Metastatic Unresectable Urothelial Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 711 (final count)
- Started
- Jan 13, 2021
- Main results expected
- Jul 4, 2025
- Fully finished
- Jul 4, 2025
- Results posted
- Jun 2, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to 42 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04527991 · record last updated 2026-06-02 · checked 2026-11-09 15:47 UTC